NATICK, Mass. - Allurion Technologies, Inc. (NYSE: ALUR), a company focused on obesity treatment solutions, has expanded its intellectual property portfolio with a newly issued U.S. patent.

Allurion's flagship offering, the Allurion Program, integrates the Allurion Gastric Balloon, a swallowable device that aids in weight loss without the need for a surgical procedure. The program ...

The U.S. Patent and Trademark Office granted Patent No. 12,209,677, which pertains to advancements in Allurion's proprietary Balloon technology, particularly improving the precision of the valve ...

NATICK, Mass., January 21, 2025--(BUSINESS WIRE)--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today ...

NYSE:ALUR) Allurion Announces Notification of Issuance of New U.S. Patent on Next-Generation Weight Loss Device for the Treatment of Obesity ...

The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less™ gastric balloon for weight loss with the ...

Allurion cited prior studies demonstrating that its gastric balloon, combined with its Virtual Care Suite, has helped patients lose weight while maintaining or even increasing muscle mass.

The Allurion swallowable intragastric balloon offers a safe, effective and minimally invasive method of losing weight.